{"id":4709,"date":"2001-07-30T20:08:45","date_gmt":"2001-07-30T19:08:45","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=4709"},"modified":"2014-06-11T17:19:21","modified_gmt":"2014-06-11T17:19:21","slug":"role-of-codon-69-variants-in-reduced-susceptibility-to-nucleoside-analogues","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/4709","title":{"rendered":"Role of codon-69 variants in reduced susceptibility to nucleoside analogues"},"content":{"rendered":"

Simon Collins and Polly Clayden, HIV i-Base<\/strong><\/p>\n

Winters and Merigan analysed the occurrence and prevalence of codon-69 mutations performed from the Stanford RT and Protease Sequence Database<\/strong> [1].<\/p>\n

The T69D mutation has been associated with reduced susceptibility to zalcitabine, however several other mutations at codon 69 have been observed in antiretroviral-treated people.<\/p>\n

Codon-69 variants were found in 127\/602 people treated with nucleoside analogues, but not in 330 drug-naive people and were significantly more prevalent in heavily treated patients. Treatment history revealed that a majority of people with codon-69 mutations had been treated with zalcitabine. However many patients who had never previously taken zalcitabine developed codon-69 mutations during antiretroviral therapy, including zidovudine monotherapy.<\/p>\n

In vitro assays showed a viral construct containing T69N had reduced susceptibility to zidovudine, didanosine and zalcitabine, a T69S to zalcitabine and a T69A to zidovudine. These data suggest that the T69D mutation is not the only codon-69 variant associated with resistance nor is zalcitabine the only drug affected by codon-69 variants.<\/p>\n

Reference:<\/p>\n

    \n
  1. Winters MA et al. Variants other than aspartic acid at codon 69 of the HIV-1 reverse transcriptase gene affect susceptibility to nucleoside analogues. Antiviral Therapy 2001; 6 (Supplement1):56. Abstract 75<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins and Polly Clayden, HIV i-Base Winters and Merigan analysed the occurrence and prevalence of codon-69 mutations performed from the Stanford RT and Protease Sequence Database [1]. The T69D mutation has been associated with reduced susceptibility to zalcitabine, however …<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,36],"tags":[112],"class_list":["post-4709","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-drug-resistance","tag-idrw-15th-2006"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/4709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=4709"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/4709\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=4709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=4709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=4709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}